Business
KDA Group Becomes the Majority Shareholder of Cannorth Medic Inc., a Company in the Cannabis Field for Medical Purposes
(via TheNewswire) Thetford Mines, Quebec / TheNewswire / July 3, 2018 - KDA Grou...
About this update from Kda Group Inc.
[{"type":"text","content":"KDA Group Becomes the Majority Shareholder of Cannorth Medic Inc., a Company in the Cannabis Field for Medical Purposes(via TheNewswire)\n\n \n \n\n \n \nThetford Mines, Quebec / TheNewswire / July 3, 2018 - KDA Group Inc. (TSXV: KDA) (\"KDA Group\" or the \"Corporation\") is proud to announce that it has signed an agreement for the acquisition of 51% of CanNorth Medic Inc. \n\n\n \n \"KDA Group is pursuing its mission to develop solutions and services for healthcare providers, and ultimately, to contribute to the well-being of the general public. This majority shareholder position will allow us to offer patients innovative cannabis-based medical products\" explained Marc Lemieux, President and CEO of KDA Group.\n\n\n \nTHE POTENTIAL OF MEDICAL CANNABIS \n\n\n \n\"It has been established that 40%-60% of medications on the global market originate from plant extracts, including recent, highly effective chemotherapy agents such as taxanes. The use of cannabinoids, like all medications, must take place in well-researched and recognized fields such as oncology and chronic pain, among others. The undeniable potential for cannabinoids to replace other medications that have major side effects should foster the introduction of medical derivatives of cannabis in clinicians' treatment arsenal, for the ultimate benefit of patients. Despite conclusive medical literature, the proven therapeutic benefits of cannabinoids continue to be greatly underestimated and underused among the general public and in the medical community.\" \n\n\n \nDr. Eric Poirier, Surgical Oncologist practising at the Centre Hospitalier Universitaire de Quebec\n\n\n \nAccording to Dr. Poirier, it is unfortunate, even today, that pharmacological derivatives of cannabis sometimes receive negative press by being misleadingly associated with recreational use and its potential for abuse. Medical and recreational use of cannabis are two completely different issues.\n\n\n \nFor example, as reported by D.W. Bowles et al., the medical use of cannabis in oncology represents less than 3% of all prescriptions in the United States, compared with 8%-23% in the Netherlands.1 The legalization of medical cannabis production in Canada will also lead to advanced scientific research to identify the most active therapeutic molecules and their best delivery methods. As with all approved medic...